Key Clinical Data on ABIOMED's Ventricular Assist Devices Presented at American Society of Extra-Corporeal Technology Conference.

DANVERS, Mass. and LAS VEGAS -- ABIOMED, Inc. (NASDAQ: ABMD), today announced the showcase of its AB5000(TM) Circulatory Support System at the American Society of Extra-Corporeal Technology's (AmSECT) 44th Annual International Conference. ABIOMED will occupy booth #414 at the AmSECT Conference which is being held at the Flamingo Hilton in Las Vegas from April 20-23.

The following key presentations are scheduled at the conference on April 21, 2006:

--"Off-pump LVAD Supported Myocardial Revascularization During Post Infarct Cardiogenic Shock (CS)," by Dr. Daniel Raess, Director of the Cardiac Surgery Program at St. Francis Hospital and Attending Staff at The Indiana Heart Hospital.

--"Improving Outcomes in Ventricular Assist Device Patients Transferred from Spoke Hospitals and Converted to an Ambulatory Device at Hub Hospitals," by Dr. Mark Anderson, Associate Professor of Surgery and Chief Section of Cardiac Surgery at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.

"ABIOMED continues to provide clinical experts with data to increase recovery awareness and improve patient outcomes with our Ventricular Assist Devices, which are designed for the most desirable result--recovery of the function of their heart after an acute heart failure event," said Michael R. Minogue, Chairman, President and Chief Executive Officer of ABIOMED. "We have the exclusive labeling on circulatory support for cardiac recovery and we are encouraged by the trend of favorable clinical data and growing acceptance of the use of our devices following inotropic and intra-aortic balloon pump support."

To date, more than 8,000 patients worldwide have been supported with these devices. Patients who have recovered included those suffering from cardiogenic shock resulting from myocardial infarction, myocarditis, postpartum cardiomyopathy, ventricular septal defect, refractory arrhythmias, failed heart transplants, right ventricular assistance with implantable LVAD (Left Ventricular Assist Device), and post cardiotomy cardiogenic shock (PCCS). ABIOMED's devices encourage recovery and are easier to implant, utilizing cannulae inserted through a small incision, rather than more traumatic bridge-to-transplant devices that core the ventricles and require heart-lung machines for implantation. The ABIOMED(R) AB5000(TM) System also allows patients to walk with the support of the console, which helps recovery.

ABOUT ABIOMED

Based in Danvers, Massachusetts, ABIOMED, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA products are not yet available for sale in the United States. The Company's AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.